From Scalpel to Syringe: Can Tirzepatide Bridge the Gap Between Pharmacotherapy and Bariatric Surgery?

This review evaluates whether tirzepatide, a dual GIP/GLP-1 receptor agonist, addresses the historical therapeutic gap between conservative lifestyle modifications and bariatric surgery in obesity management. Based on an analysis of the SURMOUNT trials, real-world data, and pharmacoeconomic models, tirzepatide demonstrates significant clinical efficacy, achieving over 20% total body weight reduction—approaching the outcomes of sleeve gastrectomy under controlled trial conditions. However, real-world effectiveness is frequently limited by high therapy discontinuation rates, contrasting with the anatomically enforced compliance characteristic of surgical interventions. Consequently, rather than rendering metabolic surgery obsolete, tirzepatide modifies current treatment algorithms. It offers demonstrated clinical utility as a neoadjuvant optimization tool prior to surgery, a bridge to solid organ transplantation, and a rescue therapy for post-bariatric weight regain. Ultimately, tirzepatide serves as an effective adjunctive and alternative therapy, complementing rather than replacing surgical interventions in the chronic management of obesity.